Did you know?
ChinaBio® LLC is a consulting and advisory firm that helps Western companies come to China. We assist our clients with China strategy development, market research and analysis, partner/technology searches, competitive surveys, and market entry planning.

>> Learn more…
Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

PharmaEngine Acquires China Rights to Nanobiotix Cancer Product

publication date: Aug 6, 2012
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
PharmaEngine of Taiwan acquired Asia-Pacific rights (including China) to a radiology-enhancing nanomedicine product from Nanobiotix S.A., a French company. NBTXR3 is currently undergoing a Phase I study trial in Europe as a treatment for soft tissue sarcoma. According to Nanobiotix, NBTXR3 increases the effect of radiation by a factor of three in mouse models without affecting nearby tissue. More details....

Stock Symbol: (TWO: 4162)

Share this with colleagues:  


This article is available for purchase - please click here for details.


Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Partner Events

China Medical Affairs Summit
June 12-13, 2014
Shanghai, China


>>More events...
Our Partners
Annual Sponsors
 
Official Partners
 
Supporting Partners
 
Media Partners